AusCann Group Holdings Ltd Overview
AusCann Group Holdings is a Perth-based, formerly ASX-listed cannabinoid pharmaceutical developer that never achieved commercial scale. It was formed in 2014 as one of Australia's first licensed medicinal-cannabis ventures and listed in 2017 via a reverse takeover with backing from Canopy Growth. It then pivoted from cultivation (Chile's DayaCann JV, a Tasmanian Alkaloids partnership) toward standardised, pharmaceutical-grade dose forms, culminating in the Neuvis® SEDDS hard-shell capsule launched in February 2020. The 2021 scrip acquisition of veterinary developer CannPal added an animal-health pipeline that was fully impaired within 15 months. Since 2022 AusCann has been in managed wind-down and monetisation mode. It sold its Wangara facility, lent heavily to European Cannabis Corporation (EuroCann/ECC, with A$9.6m later impaired), and was removed from the ASX in 2024. In April 2026 it sold its 48% CannPal stake to Argent BioPharma for 20m RGT shares and granted Argent an option over the Neuvis IP. Today it is effectively an unlisted holding vehicle for residual IP, an ECC equity interest and Argent shares.
Company's own description (FY2023 Annual Financial Statements): AusCann describes its principal activity as developing a differentiated portfolio of innovative, standardised cannabinoid-based medicines that expand the therapeutic applications of cannabis for both people and pets. It positions itself as supplying healthcare professionals and veterinarians with reliable pharmaceutical and nutraceutical products backed by safety, quality and efficacy data, in jurisdictions with relevant legislation.
Independent characterisation. In substance, AusCann has evolved through four business models:
-
Cultivator / supply-chain aggregator (2014–2018). Licences, cultivation plans (Norfolk Island, then Tasmania with Tasmanian Alkaloids, plus the DayaCann JV in Chile) and a distribution arrangement with Australian Pharmaceutical Industries.
-
Specialty pharma formulator (2018–2022). The proprietary self-emulsifying drug delivery system (SEDDS) powder formulation became Neuvis® hard-shell capsules, sold under the TGA Special Access Scheme Category B (SAS-B). The business was a B2B2C product model: prescribers recommend, pharmacies dispense. Sales never exceeded roughly A$84k in any year, and COGS exceeded sales in FY2022. Management itself stated that Neuvis was uneconomic at the existing production cost.
-
Human plus animal health pipeline (2021–2023). Through CannPal: CPAT-01 (THC/CBD canine osteoarthritis pain, Phase II), DermaCann® (CBD nutraceutical for canine atopic dermatitis) and MicroMAX® (CSIRO-licensed microencapsulation).
-
Asset-holding / transactional vehicle (2022–present). Its revenue comprised R&D tax incentive refunds, rental income from the Wangara facility (until June 2023) and accrued interest on ECC loans. It also held an exclusive AU/NZ agency for ECC's German EU-GMP HAPA pharm flower and extracts (expanded July 2023). The commercial outcome of that agency is not publicly disclosed.
Revenue model mix (FY2023, audited): product sales nil; government grants 1,249 (57.6% of total income); interest 619 (28.5%); rent 302 (13.9%). Total income was 2,170 A$000. Licensing income is nil to date. Prospective licensing or royalty streams exist only via the Argent Neuvis option, which carries a production royalty in AusCann's favour if exercised.
Value-chain position: formerly an upstream licence holder, then a mid-stream formulator using contract manufacturers (Ausphex Pty Ltd process development for Neuvis, Nov 2021, A$195k commitment). It has no owned manufacturing today.
Customer types / end-markets: Australian prescribers and pharmacies (human medicinal cannabis, SAS-B and Authorised Prescriber pathways). Veterinarians and pet owners were targeted via CannPal (US FDA-CVM INAD file established for CPAT-01). European pharmaceutical markets were addressed indirectly via ECC and the SEDDS licence granted to ECC for Europe.
Strategy
Stated strategy themes (FY2023 AFS):
-
Develop a differentiated portfolio of standardised cannabinoid medicines for people and pets.
-
Provide prescribers and veterinarians with products backed by robust safety, quality and efficacy data.
-
Operate in jurisdictions offering a compelling return on investment.
-
Actively review the R&D portfolio "with a view to undertake a transaction or a series of transactions which may involve strategic acquisitions and disposals."
Initiatives in the last ~24–36 months:
Medium-term financial targets / guidance: none publicly disclosed. ESG and sustainability commitments: none disclosed. Cost programmes: FY2023 disclosures emphasised operating-cost reductions (1H FY2023 cash costs down 39%), but no formal targets were given.
Products & Services
Human health (Medicinal Cannabis R&D segment)
| Product / platform | Description & capabilities | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| Neuvis® hard-shell capsules | Proprietary SEDDS technology combining silica, cannabis extract, MCT oil and excipients into a free-flowing powder that can deliver single cannabinoids or ratios. The powder is encapsulated in hard-shell capsules in blister packs. Previously launched ratios: 2.5:2.5 mg and 10:10 mg THC:CBD for chronic pain (per vendor summary). A Phase 1 PK/safety study in 25 subjects met all endpoints (FY2021). The FY2023 process-improvement plan delivered longer shelf life (reduced THC degradation) and shorter manufacturing time. Argent claims 3–5× bioavailability and patents to 2038+ (counterparty claim). | Australian prescribers and pharmacies via SAS-B / Authorised Prescriber | Launched Feb 2020. Commercially uneconomic per management (FY2023). Argent holds an option over the IP, exercisable within 12 months of 13 Apr 2026 for A$2m in RGT shares plus a production royalty to AusCann. | — |
| SEDDS technology licence (Europe) | Exclusive licence to ECC of SEDDS "in its current form" for Europe, to develop a standardised dose form for Germany | ECC | Granted FY2023 | — |
| CannEpil® CMC / dossier in-licence | AusCann licensed Argent's CannEpil chemistry, manufacturing and controls data and dossier for non-epilepsy programmes | Internal pipeline | HoA Apr 2025; deferred fee plus royalties | Deferred licence fee structure |
Distribution (third-party products)
| Product | Description | Target | Status |
|---|---|---|---|
| HAPA pharm THC/CBD cannabis flowers (Cannabis Flos) | German EU-GMP raw flower manufactured by ECC | AU/NZ prescribers and pharmacies | Exclusive AU/NZ agency from 31 Jul 2023; A$2.25m paid as a stock deposit in FY2023 (A$2.2m stock secured) |
| HAPA pharm full-spectrum CBD extracts (<0.2% THC) | CBD concentrations from under 2% to over 25% | AU/NZ | As above |
| HAPA pharm THC/CBD full-spectrum extracts | Multiple concentrations; individualised production | AU/NZ | As above; ECC supplies TGO 93 compliance documentation |
Sales volumes under the agency are not publicly disclosed.
Animal health (CannPal — held 2021–2026, now Argent's)
| Asset | Description | Status at exit |
|---|---|---|
| CPAT-01 | Liquid oral veterinary medicine with standardised THC and CBD whole-plant extracts in a proprietary ratio, targeting canine pain and inflammation. Studied in over 100 dogs, including a randomised double-blind placebo-controlled trial in 46 client-owned dogs with osteoarthritis. FDA-CVM INAD file established. | Phase II at the FY2023 AFS. Argent's June 2026 quarterly reports Phase 2C dose confirmation completed and advancement toward Phase 3. |
| DermaCann® | CBD-derived nutraceutical (oral oil, patented combination with bioactive lipids) for canine skin and immune health / atopic dermatitis. A 90-day US Target Animal Safety study was completed (1H FY2022). | Development |
| MicroMAX® | CSIRO patented microencapsulation; global exclusive rights in animal therapeutics (granted FY2020) | Platform |
Accounting note: CannPal IP of A$17.49m was recognised on acquisition and fully impaired at 30 June 2022 (A$15.46m impairment after A$2.03m amortisation). Patents expire 2039–2040 and trademarks renew 2029–2030 (FY2023 AFS Note 11).
Discontinued / legacy
| Asset | Description | Status |
|---|---|---|
| DayaCann (Chile) | 50% JV cultivating medicinal cannabis in Chile for trial formulations | Sold March 2021; arbitration under Chilean law over US$1.0m deferred consideration |
| Wangara R&D facility (11 Excellence Drive) | Cultivation, extraction and NPD site in WA; leased to Source Certain International | Sold 9 Jun 2023 for A$6.74m |
| Tasmanian Alkaloids cultivation partnership | Westbury, Tasmania | Not pursued; status not publicly disclosed |
Financial Narrative
Sources: FY2023 Annual Financial Statements (audited; includes the five-year loss/EPS table in the Remuneration Report); 1H FY2023 and 1H FY2022 Appendix 4D; FY2021 results commentary (30 Aug 2021). Sales for FY2019–FY2021 come from Barchart (third-party, flagged). FY2024 onward: no annual accounts were located.
Income statement
Notes: FY2021 impairment reflects the A$2.593m inventory write-down. FY2022 impairments total A$20.26m (derived): intangibles 15,459, investment property 3,855, fixed assets 759 and inventory 183. FY2023 impairments total A$9.94m (derived): ECC loans and interest 9,615 and investment-property loss 323. EBITDA and operating income are not reported. On any definition they are deeply negative: FY2023 continuing loss before tax was -10,701, of which D&A was only 182.
Data conflict flag: Barchart shows FY2023 net income of -1,045 (A$000) versus the audited -10,919. The audited figure is used. Wikipedia's infobox lists "Revenue A$1,981,664,000 (2023)" and "Total assets A$18,450,158,000". These are scaling errors: the true figures are A$1.98m total income and A$18.45m total assets, and both relate to FY2022, not FY2023.
Margins and growth
Revenue CAGR is not meaningful (product sales were nil in both FY2019 and FY2023).
Balance sheet
FY2019 and FY2020 cash are derived by rolling back the reported net cash flows (+22,429 in FY2019, -16,142 in FY2020, -5,486 in FY2021; Barchart) from the audited FY2021 closing cash of 13,680. ECC loans totalling 8,750 at 31 Dec 2022 were reduced to nil carrying value at 30 June 2023 after 3,000 of repayments and a 9,615 impairment (including accrued interest). Goodwill: nil in all periods. Later data point: cash of A$2.586m was reported in the December 2023 quarter update (TipRanks summary of ASX release). FY2024 balances are not publicly disclosed.
Cash flow
FY2020 and FY2021 operating cash flow figures are as reported by management excluding one-off CannPal acquisition costs (FY2021 commentary). FY2023 operating cash flow includes a A$2.25m stock deposit paid to ECC.
Ratios (computed from audited figures)
ROIC, cash conversion cycle and interest coverage are not meaningful (no debt, negligible sales).
Commentary on trends, inflections and drivers
FY2019–FY2021, the cash-burn phase. AusCann raised significant equity in 2017–2019; FY2019 net cash inflow was A$22.4m. It spent it on cultivation programmes, the Wangara facility and formulation R&D. Annual losses were stable at A$7–9m. Direct R&D ran at about A$2.7–2.9m p.a., about 51% of operating outflows in FY2021. Sales were trivial even after the Neuvis launch: about A$84k in FY2021, per third-party data. The FY2021 loss included a A$2.59m write-down of resin inventory, reflecting collapsing global cannabinoid API prices. That was an early sign that the cost base of a vertically integrated Australian producer was uncompetitive. Net assets nonetheless rose to A$44.4m in FY2021 because the CannPal scrip acquisition added A$17.5m of capitalised IP.
FY2022, the impairment inflection. Within 15 months the CannPal IP was written off in full (A$15.46m). Management attributed the cannabis-sector capital-market collapse to an index drop of more than 85%. The investment property was marked down A$3.85m, and the DayaCann deferred consideration (A$1.42m) was fully provided for. The A$26.4m loss eliminated 59% of book equity. Simultaneously, management redeployed A$5m of the A$13.7m cash pile into a 7.5% secured loan to ECC. That marked the strategic shift from operator to financier and partner.
FY2023, monetisation and a second impairment. Costs were cut hard: employee costs fell 60%, R&D 64% and D&A 90%. The property sale raised A$6.48m net. However, a further A$3.75m was lent to ECC in August 2022 and A$1.0m more in FY2023 (A$4.75m advanced in FY2023 against A$3.0m repaid). The auditor qualified the 1H FY2023 review on recoverability of the A$9.06m ECC exposure. At year end A$9.62m of ECC loans and interest was impaired. Equity fell to A$7.18m, with A$7.01m of it in cash. The going-concern basis relied on the property-sale proceeds.
FY2024 onwards, the opaque period. No further audited accounts were located. Cash had fallen to A$2.59m by the December 2023 quarter. Post-balance-date notes in the FY2023 AFS disclose a further A$1.3m forwarded to ECC on 3 July 2023 and a A$1.25m convertible note issued to ECC (12.5%, 6-month term, secured). The A$1m SPP of January 2024 appears not to have completed: the proposed issue was cancelled on 15 Feb 2024. The company was then removed from the ASX in August 2024. The only post-FY2023 value realisation verifiable in public sources is the April 2026 receipt of 20,000,000 Argent BioPharma (ASX: RGT) shares at a deemed A$0.10 (A$2.0m deemed).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Product sales (AUD K) | 0 | 3 | 84 | 25 | 0 |
Cost of goods sold (AUD K) | — | — | — | -34 | 0 |
Gross profit on sales (AUD K) | — | — | — | -9 | 0 |
Government grants incl R&D tax incentive (AUD K) | — | — | — | 1,484 | 1,249 |
Rental income (AUD K) | — | — | — | 427 | 302 |
Interest revenue (AUD K) | — | — | — | 30 | 619 |
Total income (AUD K) | — | — | — | 1,982 | 2,170 |
Direct R&D expense (AUD K) | — | 2,707 | 2,948 | 1,346 | 490 |
Employee benefits expense (AUD K) | — | — | — | 1,713 | 680 |
Depreciation and amortisation (AUD K) | — | — | — | 1,838 | 182 |
Impairments and fair-value losses (AUD K) | — | — | 2,593 | 20,256 | 9,938 |
Loss before tax continuing (AUD K) | — | — | — | -24,766 | -10,701 |
Net loss after tax (AUD K) | -7,649 | -7,076 | -8,641 | -26,358 | -10,919 |
Basic and diluted EPS (AUD cents) | -2.48 | -2.24 | -2.45 | -5.98 | -2.47 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 |
|---|---|---|
Gross margin on sales (%) | -38 | — |
Net loss / total income (%) | -1,330 | -503 |
Total income growth YoY (%) | — | 9.5 |
Balance Sheet
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Cash and equivalents (AUD K) | 35,310 | 19,168 | 13,680 | 5,717 | 7,010 |
Total assets (AUD K) | — | — | — | 18,450 | 7,330 |
Investment property (AUD K) | — | — | 11,111 | 7,200 | 0 |
Loans to ECC (AUD K) | — | — | 0 | 5,000 | 0 |
Intangible assets (AUD K) | — | — | — | 0 | 0 |
Total liabilities (AUD K) | — | — | — | 296 | 148 |
Total borrowings (AUD K) | — | — | — | 0 | 0 |
Lease liabilities (AUD K) | — | — | 85 | 40 | 0 |
Net debt (AUD K) | — | — | -13,680 | -5,717 | -7,010 |
Total equity (AUD K) | — | 34,636 | 44,428 | 18,154 | 7,182 |
Working capital (AUD K) | — | — | — | 6,777 | 7,169 |
Accumulated losses (AUD K) | — | — | -49,524 | -75,139 | -86,038 |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Net operating cash flow (AUD K) | — | -10,551 | -5,759 | -2,831 | -3,328 |
Capex incl building improvements (AUD K) | — | — | — | -85 | 0 |
Free cash flow (AUD K) | — | — | — | -2,916 | -3,328 |
Net loans advanced to ECC (AUD K) | — | — | — | -5,000 | -1,750 |
Proceeds from property sale (AUD K) | — | — | — | 0 | 6,482 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | 22,429 | -16,142 | -5,486 | -7,963 | 1,293 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 |
|---|---|---|
ROE on average equity (%) | -84 | -86 |
ROA on average assets (%) | — | -85 |
Current ratio (x) | 23.9 | 49.5 |
Debt to equity (x) | 0 | 0 |
Asset turnover on total income (x) | — | 0.17 |
Results by Region
| Region | FY2022 | FY2023 |
|---|---|---|
Australia total income (AUD K) | 1,982 | 2,170 |
Chile discontinued income (AUD K) | 0 | 0 |
Europe income (AUD K) | 0 | 0 |
Share Price and Share Count (million)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.34 | 0.136 | 0.10 | 0.038 | — |
Shares on issue weighted (million) | — | — | — | 440.5 | 440.5 |
Implied market cap at 30 June (AUD Mn, derived) | — | — | — | 16.7 | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None (no broker coverage identified) |
Dividend history / policy | No dividends ever paid; none expected |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No borrowings |
Capital raising history (selected) | A$5m at A$0.20 (2017 re-listing); CannPal scrip about A$17.5m (2021); A$1m SPP at A$0.016 attempted (Jan 2024, cancelled) |
Analyst Conclusions
Management guidance: none issued since the FY2023 accounts. The FY2023 directors' report expected expenditure to "further reduce" in FY2024. Consensus growth expectations: none (no coverage).
Bull case
-
Option and royalty convexity. If Argent exercises the Neuvis option before about April 2027, AusCann receives a further A$2m in RGT shares plus a perpetual production royalty. That is non-dilutive value on an asset AusCann had written off as uneconomic.
-
RGT re-rating. AusCann's main asset is now 20m RGT shares. Argent's US$5.5m CannEpil licence with Splash Beverage (Jul 2026), CannPal's Phase 2C success and its US-listing plan could lift that holding materially.
-
Hidden European value. The retained ECC/EuroCann equity interest, deliberately excluded from the Argent deal, gives exposure to EU-GMP production and German distribution as Germany's medical market expands.
Bear case
-
Track record of capital destruction. A$93m was raised against A$86m of accumulated losses, and every major capital allocation since 2021 was impaired: CannPal, ECC loans and DayaCann.
-
Shrinking deal value and illiquidity. The Argent transaction fell from about US$15m to A$2m in five months. Shareholders have no exchange liquidity and no audited accounts since FY2023.
-
Governance overlap. The same small group of directors spans AusCann, ECC and Argent, and related-party transactions (A$1 CannPal sale, ECC loans) raise questions over whose interests drive outcomes.
Key catalysts and monitorables (next 12 months)
Analyst verdict. AusCann Group Holdings is best understood today not as an operating pharmaceutical company but as a residual holding vehicle at the tail end of a decade-long, largely unsuccessful attempt to build an Australian cannabinoid medicines business. The audited record is unambiguous. Between FY2019 and FY2023 the company generated cumulative product sales of roughly A$112k while recording A$60.6m of net losses. By June 2023 it had shrunk its balance sheet to A$7.2m of net assets, almost all of it cash, with no debt and no staff.
The strategic decisions of 2021–2023 consumed the remaining capital base. The CannPal acquisition was written off within 15 months, A$9.6m of loans to a closely connected European partner were impaired, and the core facility was sold at a loss. The subsequent failure to re-comply with ASX rules and the removal from the Official List in August 2024 stripped shareholders of liquidity and price discovery.
What remains has genuine, if modest, option value. That consists of 20 million Argent BioPharma shares (deemed A$2m), a call on a further A$2m plus royalty if Argent exercises the Neuvis option, an undisclosed equity interest in EuroCann, about A$32m of unrecognised tax losses (derived), and a contested US$1m Chilean receivable. Against that sit an unknown cash position (last reported A$2.59m in December 2023), an unknown liabilities position, and unresolved questions about related-party governance.
For any stakeholder, the decisive near-term monitorable is transparency. Until AusCann lodges current audited accounts, the value attributable to its 440.5 million shares cannot be responsibly estimated. On available evidence we view the equity as a speculative, illiquid residual claim whose outcome depends almost entirely on Argent BioPharma's execution rather than on any AusCann-controlled operating activity. Institutional investors should treat it as uninvestable pending disclosure; existing holders should press the board for audited accounts and a clear capital-return or wind-up plan.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background | Shares (FY2023) |
|---|---|---|---|---|
Andrew Chapman | Non-Executive Chair (from 30 Nov 2023); described as Executive Director in 2025–26 counterparty releases | Nov 2023 – (current status at AusCann not confirmed after joining Argent's board in May 2026) | MD of Merchant Group / Merchant Funds Management (historically AusCann's largest shareholder); director of ECC Pharm; Chair of Cycliq Group; former exploration geologist; graduate and postgraduate qualifications in business, finance and hospitality | — |
Robert Clifford | Independent NED | Since 1 Apr 2021 | Hospitality and food executive (Hyatt, former CEO of Perth Convention Exhibition Centre, EPICURE); Alto Cibum Consulting; former CannPal director | 624,380 |
Brett Mitchell | Independent NED | Since 29 Jun 2023 | Corporate finance (Chieftain Securities); co-founded MGC Pharmaceuticals (now Argent BioPharma); Delta Lithium; NED Uvre (UVA); BA Economics | Nil |
Tod McGrouther | Independent Chair | 14 Dec 2021 – 30 Nov 2023 | KTM Capital principal; former BT Australia and Prudential-Bache; director of ECC since 2018; NSX chair; LLB (Hons, University Medal), BFin (Hons) | Nil |
Chris Mews | NED to 29 Jun 2023; then CFO (via Merchant Group, A$5k/month) | NED Dec 2019 – Jun 2023 | CFO and Company Secretary of Merchant Group; former CFO of PolyNovo; BBus (Acc), CPA | 279,689 |
Susan Park | Company Secretary | FY2022–FY2023 | Park Advisory; ex-EY, PwC, Bankwest | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Person | Fees / salary | Super | Share-based | Total |
|---|---|---|---|---|
Tod McGrouther (Chair) | 88,000 | 0 | 0 | 88,000 |
Chris Mews | 122,750 | 0 | 0 | 122,750 |
Robert Clifford | 50,000 | 5,250 | 0 | 55,250 |
Krista Bates (to 3 Jan 2023) | 26,242 | 0 | 0 | 26,242 |
Brett Mitchell (from 29 Jun 2023) | 0 | 0 | 0 | 0 |
Layton Mills (CEO, resigned) | 272,542 | 21,101 | 7,734 | 301,377 |
Dr Margaret Curtis | 204,840 | 17,155 | 7,058 | 229,053 |
Total KMP | 764,374 | 43,506 | 14,792 | 822,672 |
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Merchant Funds Management / Merchant Group | Largest shareholder (2019); exact % not publicly disclosed in retrieved sources | ASX release 4 Nov 2019 |
Layton Mills (DJS Family A/C) | 11,387,582 shares (2.58%) | Motley Fool holder data (historical) |
Canopy Growth | About 11% at 2016 listing; current holding not disclosed | Ganjapreneur (2016) |
Competitive Landscape
Key Competitors
| Competitor | Listing | Segment overlap | Relative positioning vs AusCann |
|---|---|---|---|
Cann Group | ASX: CAN | Australian cultivation and manufacture | Far larger asset base; itself went into voluntary suspension in Nov 2023 |
Little Green Pharma | ASX: LGP | WA-based GMP cultivator and products | Commercial-scale revenue; a direct WA peer |
Argent BioPharma (formerly MGC Pharmaceuticals) | ASX: RGT | Cannabinoid pharma (CannEpil, CimetrA) | Former competitor, now acquirer and partner |
Zelira Therapeutics | ASX: ZLD | Clinical cannabinoid medicines | Clinical-stage peer |
Bod Science | ASX: BOD | CBD products, pharma pathway | Consumer and pharma hybrid |
Emyria | ASX: EMD | Real-world-data-driven cannabinoid / psychedelic medicines | Clinical-data model |
Neurotech International | ASX: NTI | Cannabinoid paediatric neurology | Clinical-stage peer |
Incannex Healthcare | Nasdaq: IXHL (formerly ASX: IHL) | Cannabinoid combination drugs | Re-domiciled to the US |
Vitura Health | ASX: VIT | Distribution and telehealth for medicinal cannabis | Downstream channel leader |
Zoetis / Elanco | NYSE | Canine osteoarthritis pain (vs CPAT-01) | Global animal-health majors |
Competitor Detail
| Metric | AusCann FY2023 |
|---|---|
Product revenue (AUD K) | 0 |
Revenue growth (%) | -100 |
Net margin (%) | n/m |
Direct R&D (AUD K) | 490 |
Recent Developments
It includes counterparty (Argent) disclosures, which are now the main public source on AusCann.



